Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRL1 | P41146 | 1/20 | 0.49 |
| ▸ | MAOB | P27338 | 5/20 | 0.42 |
| ▸ | KDM1A | O60341 | 1/20 | 0.42 |
| ▸ | MAOA | P21397 | 3/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL12540104 | 0.75 | OPRL1 (0.56) | OPRL1MAOBKDM1AMAOA | |
| Hydrochloric Acid SCHEMBL12540425 | 0.75 | OPRL1 (0.56) | OPRL1MAOBKDM1AMAOA | |
| Methyl Alcohol SCHEMBL12814774 | 0.72 | OPRL1 (0.53) | OPRL1MAOBKDM1AMAOA | |
| SCHEMBL14337143 | 0.72 | OPRL1 (0.67) | OPRL1MAOBKDM1AMAOA | |
| SCHEMBL11572399 | 0.72 | OPRL1 (0.52) | OPRL1MAOBKDM1AMAOA | |
| SCHEMBL18383462 | 0.71 | MAOA (0.56) | OPRL1MAOBKDM1AMAOA | |
| Ammonia Solution, Strong SCHEMBL27588639 | 0.71 | DPP4 (0.42) | MAOBMAOA | |
| Hydrochloric Acid SCHEMBL11569798 | 0.71 | OPRL1 (0.50) | OPRL1MAOBKDM1AMAOA | |
| SCHEMBL29357755 | 0.70 | MAOB (0.50) | OPRL1MAOBKDM1AMAOA | |
| SCHEMBL14880513 | 0.70 | MAOB (0.50) | OPRL1MAOBKDM1AMAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020021015-A1 | NEW IMIDAZOPYRIDINE DERIVATIVES FOR TREATING PAIN AND PAIN RELATED CONDITIONS | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2020-01-30 | — | — | WO | claimed |
| WO-2020021015-A1 | NEW IMIDAZOPYRIDINE DERIVATIVES FOR TREATING PAIN AND PAIN RELATED CONDITIONS | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2020-01-30 | — | — | WO | disclosed |
| EP-2260022-A1 | SUBSTITUTED CYCLOHEXYLDIAMINES | Grünenthal GmbH (DE) | 2010-12-15 | — | — | EP | disclosed |
| WO-2009118174-A1 | SUBSTITUTED CYCLOHEXYLDIAMINES | Grünenthal GmbH (DE) | 2009-10-01 | — | — | WO | disclosed |
| US-20090247591-A1 | SUBSTITUTED CYCLOHEXYLDIAMINES | GRUNENTHAL GMBH (DE) | 2009-10-01 | — | — | US | disclosed |
| EP-1560809-A1 | CYCLOHEXYLUREA DERIVATIVES | Grünenthal GmbH (DE) | 2005-08-10 | — | — | EP | disclosed |
| WO-2004043909-A1 | CYCLOHEXYLUREA DERIVATIVES | Grünenthal GmbH (DE) | 2004-05-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090247591-A1 | SUBSTITUTED CYCLOHEXYLDIAMINES | OPRL1, OPRD1, OPRK1 | OPRL1 1/4885MAOB 607/4885KDM1A 1948/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.